Jenna L. Voellinger

571 total citations
11 papers, 408 citations indexed

About

Jenna L. Voellinger is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jenna L. Voellinger has authored 11 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Hematology and 3 papers in Oncology. Recurrent topics in Jenna L. Voellinger's work include Acute Myeloid Leukemia Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Histone Deacetylase Inhibitors Research (2 papers). Jenna L. Voellinger is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Histone Deacetylase Inhibitors Research (2 papers). Jenna L. Voellinger collaborates with scholars based in United States. Jenna L. Voellinger's co-authors include Edward J. Kelly, Danny D. Shen, Thomas Neumann, Kenneth E. Thummel, Brian D. Chapron, Jonathan Himmelfarb, Zhican Wang, Kimberly A. Muczynski, Yoshiyuki Yamaura and Elijah J. Weber and has published in prestigious journals such as Blood, Cancer Research and Kidney International.

In The Last Decade

Jenna L. Voellinger

11 papers receiving 396 citations

Peers

Jenna L. Voellinger

ONCOL

HEMAT

PHEOH

Pedro Caetano-Pinto Germany

Tom T.G. Nieskens Netherlands

Ganesh Moorthy United States

Yutaka Nakajima Japan

Maciej Niedźwiecki Poland

Renyu Lin China

Christine Mall United States

Jian Ding China

Jialin Luo China

Pedro Caetano-Pinto Germany

Jenna L. Voellinger

168 ×1.0

126 ×0.8

90 ×0.8

ONCOL

17 ×0.2

HEMAT

21 ×0.5

PHEOH

Citations per year, relative to Jenna L. Voellinger Jenna L. Voellinger (= 1×) peers Pedro Caetano-Pinto

Countries citing papers authored by Jenna L. Voellinger

Since Specialization

Citations

This map shows the geographic impact of Jenna L. Voellinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenna L. Voellinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenna L. Voellinger more than expected).

Fields of papers citing papers by Jenna L. Voellinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenna L. Voellinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenna L. Voellinger. The network helps show where Jenna L. Voellinger may publish in the future.

Co-authorship network of co-authors of Jenna L. Voellinger

This figure shows the co-authorship network connecting the top 25 collaborators of Jenna L. Voellinger. A scholar is included among the top collaborators of Jenna L. Voellinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenna L. Voellinger. Jenna L. Voellinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Passey, Chaitali, Jenna L. Voellinger, Leonid Gibiansky, et al.. (2023). Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors. CPT Pharmacometrics & Systems Pharmacology. 12(9). 1262–1273. 8 indexed citations

Gibiansky, Leonid, Chaitali Passey, Jenna L. Voellinger, et al.. (2022). Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors. CPT Pharmacometrics & Systems Pharmacology. 11(10). 1358–1370. 11 indexed citations

Fathi, Amir T., Harry P. Erba, Jeffrey E. Lancet, et al.. (2018). A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 132(11). 1125–1133. 55 indexed citations

Chang, Shih‐Yu, Jenna L. Voellinger, Kirk P. Van Ness, et al.. (2017). Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity. Toxicology in Vitro. 40. 170–183. 31 indexed citations

Voellinger, Jenna L., et al.. (2017). Abstract CT120: Assessment of myeloblast CD33 receptor occupancy (RO) by vadastuximab talirine in patients with acute myeloid leukemia (AML) receiving monotherapy treatment. Cancer Research. 77(13_Supplement). CT120–CT120. 1 indexed citations

Weber, Elijah J., Alenka Chapron, Brian D. Chapron, et al.. (2016). Development of a microphysiological model of human kidney proximal tubule function. Kidney International. 90(3). 627–637. 191 indexed citations

Yang, Jay, Farhad Ravandi, Anjali S. Advani, et al.. (2016). A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). Blood. 128(22). 340–340. 5 indexed citations

Erba, Harry P., Moshe Levy, Sumithira Vasu, et al.. (2016). A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood. 128(22). 211–211. 23 indexed citations

Bixby, Dale L., Anthony S. Stein, Amir T. Fathi, et al.. (2016). Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML). Blood. 128(22). 590–590. 25 indexed citations

10.

Risler, Linda J., Bhagwat Prasad, Justina C. Calamia, et al.. (2014). Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochemical Pharmacology. 92(4). 690–700. 32 indexed citations

11.

Kelly, Edward J., Zhican Wang, Jenna L. Voellinger, et al.. (2013). Innovations in preclinical biology: ex vivo engineering of a human kidney tissue microperfusion system. Stem Cell Research & Therapy. 4(S1). S17–S17. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact